Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals is the maker of PEDMARK™ (Sodium Thiosulfate Injection), which is indicated to reduce the risk of ototoxicity associate with cisplatin in pediatric patients 1 month of age and older with localized non-metastatic sold tumors.  The impact of ototoxicity may be permanent, severe, and profound—with the potential to significantly impair cognitive performance and the development of social and language skills. We are committed to sparing children further hardship and helping to protect their ears from the threat of cisplatin-induced ototoxicity.  Detailed information on PEDMARK™ (Sodium Thiosulfate Injection) including Important Safety Information can be found at: www.pedmarkhcp.com.